A new hi-tech prostate cancer drug has already demonstrated a 'positive impact on the quality of life', the Institute of Cancer Research said today, as the treatment trials in the capital.
Professor Johann de Bono from the institute, who led the Affirm trial, said:
"Enzalutamide is a much needed development in prostate cancer treatment and will provide a new option for the increasing number of men with advanced prostate cancer in the UK whose disease has become resistant to first-line hormonal treatments and who have had docetaxel chemotherapy.
"Enzalutamide has already demonstrated a positive impact on quality of life whilst increasing the life-span of patients with this common disease.
"It's use will bring significant benefits, establishing it as a key component of advanced prostate cancer treatment in the UK."
More top news
Kouider's campaign of hate began when the Boyzone star stopped paying her tens of thousands of pounds in rent and living expenses.
Mark and Sabrina lived together for two years in Queensway, London, before she disappeared without warning.
The prosecution told the jury the Frenchman had "punched above his weight" when it came to the love of his life.